A review of amphetamine extended release once-daily options for the management of attention-deficit hyperactivity disorder.

IF 3.4 2区 医学 Q2 CLINICAL NEUROLOGY
Expert Review of Neurotherapeutics Pub Date : 2024-04-01 Epub Date: 2024-02-23 DOI:10.1080/14737175.2024.2321921
Kendall Abbas, Elizabeth W Barnhardt, Patricia L Nash, Maria Streng, Daniel L Coury
{"title":"A review of amphetamine extended release once-daily options for the management of attention-deficit hyperactivity disorder.","authors":"Kendall Abbas, Elizabeth W Barnhardt, Patricia L Nash, Maria Streng, Daniel L Coury","doi":"10.1080/14737175.2024.2321921","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Amphetamine preparations are one of the two categories of stimulant medications approved for the treatment of attention deficit hyperactivity disorder (ADHD). Optimal treatment of ADHD aims to reduce core symptoms for as much of the waking hours as possible, leading to longer-acting delivery formats. In addition, the pediatric population commonly has difficulty swallowing pills and manufacturers have developed a variety of options to facilitate this concern. These include chewable tablets, capsules that may be sprinkled on soft food, liquids and transdermal patches.</p><p><strong>Areas covered: </strong>This article reviews the once-daily extended-release preparations currently available for amphetamine compounds, their pharmacodynamics, and common adverse effects.</p><p><strong>Expert opinion: </strong>There is an extensive evidence base supporting use of amphetamine preparations in the treatment of ADHD. Rapid onset of action and a favorable side effect profile make these widely used. The availability of once-daily extended-release chewable tablets, capsules that can be opened and sprinkled, and liquid formulations provides clinicians with multiple options to meet the specific needs of patients with difficulty swallowing whole pills.</p>","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"421-432"},"PeriodicalIF":3.4000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Neurotherapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737175.2024.2321921","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/2/23 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Amphetamine preparations are one of the two categories of stimulant medications approved for the treatment of attention deficit hyperactivity disorder (ADHD). Optimal treatment of ADHD aims to reduce core symptoms for as much of the waking hours as possible, leading to longer-acting delivery formats. In addition, the pediatric population commonly has difficulty swallowing pills and manufacturers have developed a variety of options to facilitate this concern. These include chewable tablets, capsules that may be sprinkled on soft food, liquids and transdermal patches.

Areas covered: This article reviews the once-daily extended-release preparations currently available for amphetamine compounds, their pharmacodynamics, and common adverse effects.

Expert opinion: There is an extensive evidence base supporting use of amphetamine preparations in the treatment of ADHD. Rapid onset of action and a favorable side effect profile make these widely used. The availability of once-daily extended-release chewable tablets, capsules that can be opened and sprinkled, and liquid formulations provides clinicians with multiple options to meet the specific needs of patients with difficulty swallowing whole pills.

安非他明缓释剂每日一次治疗注意缺陷多动障碍方案综述。
简介:苯丙胺制剂是获准用于治疗注意力缺陷多动障碍(ADHD)的两类兴奋剂药物之一。治疗注意力缺陷多动障碍(ADHD)的最佳方法是在尽可能多的清醒时间内减轻核心症状,因此需要长效给药形式。此外,儿科人群通常难以吞咽药片,因此生产商开发了多种选择来解决这一问题。这些选择包括咀嚼片、可撒在软食上的胶囊、液体和透皮贴剂:本文回顾了目前可用于苯丙胺化合物的每日一次缓释制剂、其药效学和常见不良反应:专家观点:有大量证据支持使用苯丙胺制剂治疗多动症。安非他明制剂起效迅速,副作用小,因此被广泛使用。每日一次的缓释咀嚼片、可打开并喷洒的胶囊以及液体制剂的出现,为临床医生提供了多种选择,以满足吞咽整粒药片有困难的患者的特殊需求。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Expert Review of Neurotherapeutics
Expert Review of Neurotherapeutics Medicine-Neurology (clinical)
CiteScore
7.00
自引率
2.30%
发文量
61
审稿时长
4-8 weeks
期刊介绍: Expert Review of Neurotherapeutics (ISSN 1473-7175) provides expert reviews on the use of drugs and medicines in clinical neurology and neuropsychiatry. Coverage includes disease management, new medicines and drugs in neurology, therapeutic indications, diagnostics, medical treatment guidelines and neurological diseases such as stroke, epilepsy, Alzheimer''s and Parkinson''s. Comprehensive coverage in each review is complemented by the unique Expert Review format and includes the following sections: Expert Opinion - a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results Article Highlights – an executive summary of the author’s most critical points
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信